AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 191 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 3.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $637,012 | -37.2% | 14,773 | -57.4% | 0.02% | -40.0% |
Q1 2024 | $1,015,037 | +78.3% | 34,714 | +35.8% | 0.04% | +66.7% |
Q4 2023 | $569,177 | -0.5% | 25,558 | +10.6% | 0.02% | -25.0% |
Q3 2023 | $572,121 | -33.0% | 23,116 | -23.3% | 0.03% | -30.4% |
Q2 2023 | $853,678 | -3.5% | 30,144 | -21.8% | 0.05% | -16.4% |
Q1 2023 | $884,896 | +262.7% | 38,524 | +360.2% | 0.06% | +450.0% |
Q1 2022 | $244,000 | -20.3% | 8,372 | -10.0% | 0.01% | 0.0% |
Q4 2021 | $306,000 | -41.3% | 9,307 | -17.6% | 0.01% | -44.4% |
Q3 2021 | $521,000 | -10.2% | 11,289 | +7.2% | 0.02% | -5.3% |
Q2 2021 | $580,000 | +10.3% | 10,533 | +3.5% | 0.02% | -5.0% |
Q1 2021 | $526,000 | +3.5% | 10,177 | -13.1% | 0.02% | -9.1% |
Q4 2020 | $508,000 | +36.2% | 11,713 | +9.8% | 0.02% | +15.8% |
Q3 2020 | $373,000 | -48.1% | 10,665 | -20.6% | 0.02% | -52.5% |
Q2 2020 | $718,000 | +82.2% | 13,434 | +21.0% | 0.04% | +33.3% |
Q1 2020 | $394,000 | -45.5% | 11,099 | -26.7% | 0.03% | -3.2% |
Q4 2019 | $723,000 | +87.3% | 15,148 | +27.3% | 0.03% | +55.0% |
Q3 2019 | $386,000 | -38.5% | 11,899 | -5.4% | 0.02% | -33.3% |
Q2 2019 | $628,000 | -34.2% | 12,583 | -11.1% | 0.03% | -34.8% |
Q1 2019 | $955,000 | +49.0% | 14,155 | +1.9% | 0.05% | +15.0% |
Q4 2018 | $641,000 | -51.8% | 13,891 | -19.4% | 0.04% | -20.0% |
Q3 2018 | $1,330,000 | +2.6% | 17,241 | +12.0% | 0.05% | -3.8% |
Q2 2018 | $1,296,000 | -0.2% | 15,388 | -3.1% | 0.05% | 0.0% |
Q1 2018 | $1,298,000 | +49.2% | 15,875 | +4.3% | 0.05% | +52.9% |
Q4 2017 | $870,000 | -24.1% | 15,226 | -11.4% | 0.03% | -29.2% |
Q3 2017 | $1,147,000 | +39.5% | 17,182 | +7.6% | 0.05% | +29.7% |
Q2 2017 | $822,000 | +5.0% | 15,971 | +19.1% | 0.04% | +5.7% |
Q1 2017 | $783,000 | +29.9% | 13,413 | -7.1% | 0.04% | +25.0% |
Q4 2016 | $603,000 | -31.2% | 14,443 | -12.9% | 0.03% | -33.3% |
Q3 2016 | $876,000 | +45.5% | 16,580 | +15.3% | 0.04% | +44.8% |
Q2 2016 | $602,000 | -0.2% | 14,381 | -3.2% | 0.03% | -6.5% |
Q1 2016 | $603,000 | -49.8% | 14,860 | -19.6% | 0.03% | -45.6% |
Q4 2015 | $1,200,000 | -7.9% | 18,491 | +0.2% | 0.06% | -23.0% |
Q3 2015 | $1,303,000 | – | 18,454 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Caligan Partners LP | 514,711 | $22,194,338 | 5.19% |
ACUTA CAPITAL PARTNERS, LLC | 78,700 | $3,393,544 | 2.86% |
Bellevue Group AG | 3,879,548 | $167,286,110 | 2.72% |
Parkman Healthcare Partners LLC | 446,416 | $19,249,458 | 2.58% |
Eagle Health Investments LP | 330,830 | $14,265,390 | 2.50% |
SECTOR GAMMA AS | 121,844 | $5,253,913 | 1.96% |
Frazier Life Sciences Management, L.P. | 871,974 | $37,599,519 | 1.76% |
BVF INC/IL | 1,190,107 | $51,317,414 | 1.44% |
Rock Springs Capital Management LP | 1,044,261 | $45,028,534 | 1.36% |
FARALLON CAPITAL MANAGEMENT LLC | 5,654,502 | $243,822,126 | 1.15% |